Literature DB >> 15614581

Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival.

Matthias Preusser1, Stefan Wolfsberger, Christine Haberler, Helene Breitschopf, Thomas Czech, Irene Slavc, Adrian L Harris, Till Acker, Herbert Budka, Johannes A Hainfellner.   

Abstract

We investigated angiogenic patterns and expression of hypoxia-related tissue factors and their prognostic impact in 100 cases of intracranial ependymoma. Angiogenic patterns were evaluated by anti-CD34 immunolabeling. Hypoxia-related factors carbonic anhydrase 9 (CA9) and hypoxia-inducible factor 1 alpha (HIF-1alpha) were visualized by immunohistochemistry, and vascular endothelial growth factor (VEGF) mRNA by in situ hybridization. Expression patterns of VEGF and CA9 are similar with regard to distribution (perinecrotic) and extent. HIF-1alpha expression occurs in a significantly smaller fraction of cases and only in a few tumor cells without clear association with necrosis. Expression of VEGF and CA9, but not HIF-1alpha, is associated with a bizarre angiogenic subtype. Combined expression of two or three hypoxia markers (high hypoxia score) associates with presence of necrosis, high proliferation index, bizarre vascular pattern, and increased cellularity. Univariate analysis indicated that patients with high hypoxia score had significantly shorter survival. On multivariate analysis, only proliferation index and extent of resection remained independent predictive factors. We conclude that bizarre vascular pattern, necrosis and high hypoxia score are frequently detectable in intracranial ependymoma, but seem less important for patient outcome than tumor cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15614581     DOI: 10.1007/s00401-004-0938-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  14 in total

Review 1.  Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis.

Authors:  Klara Kuncova; Ales Janda; Pavel Kasal; Josef Zamecnik
Journal:  Pathol Oncol Res       Date:  2009-03-20       Impact factor: 3.201

2.  Prognostic marker analysis in pediatric intracranial ependymomas.

Authors:  Roger E McLendon; Eric Lipp; Diane Satterfield; Melissa Ehinger; Alan Austin; Debra Fleming; Kathryn Perkinson; Michaela Lefaivre; David Zagzag; Benjamin Wiener; Sri Gururangan; Herbert Fuchs; Henry S Friedman; James E Herndon; Patrick Healy
Journal:  J Neurooncol       Date:  2015-01-07       Impact factor: 4.130

3.  Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells.

Authors:  Daizo Yoshida; Kyongson Kim; Masahiro Noha; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-07-30       Impact factor: 4.130

4.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Authors:  Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

Review 5.  The biology of ependymomas and emerging novel therapies.

Authors:  Amr H Saleh; Nardin Samuel; Kyle Juraschka; Mohammad H Saleh; Michael D Taylor; Michael G Fehlings
Journal:  Nat Rev Cancer       Date:  2022-01-14       Impact factor: 69.800

Review 6.  Biology and management of ependymomas.

Authors:  Jing Wu; Terri S Armstrong; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2016-03-28       Impact factor: 12.300

7.  Cytokine and growth factor responses after radiotherapy for localized ependymoma.

Authors:  Thomas E Merchant; Chenghong Li; Xiaoping Xiong; M Waleed Gaber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-18       Impact factor: 7.038

8.  Bevacizumab for recurrent ependymoma.

Authors:  R M Green; T F Cloughesy; R Stupp; L M DeAngelis; E A Woyshner; D E Ney; A B Lassman
Journal:  Neurology       Date:  2009-11-17       Impact factor: 9.910

9.  Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma.

Authors:  Lucas Moreno; Sergey Popov; Alexa Jury; Saffa Al Sarraj; Chris Jones; Stergios Zacharoulis
Journal:  J Neurooncol       Date:  2012-11-08       Impact factor: 4.130

10.  Single-Cell RNA Sequencing of Childhood Ependymoma Reveals Neoplastic Cell Subpopulations That Impact Molecular Classification and Etiology.

Authors:  Austin E Gillen; Kent A Riemondy; Vladimir Amani; Andrea M Griesinger; Ahmed Gilani; Sujatha Venkataraman; Krishna Madhavan; Eric Prince; Bridget Sanford; Todd C Hankinson; Michael H Handler; Rajeev Vibhakar; Ken L Jones; Siddhartha Mitra; Jay R Hesselberth; Nicholas K Foreman; Andrew M Donson
Journal:  Cell Rep       Date:  2020-08-11       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.